Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy
Yoshio Nakamura(Keio University), Naoya Yamazaki, Keiji Tanese(Toho University), Noboru Yamamoto(Tokyo National Hospital), Arata Tsutsumida, Takeru Funakoshi(Keio University), Akira Takahashi, Kenjiro Namikawa(Tokyo Metropolitan Komagome Hospital), Masayuki Amagai(RIKEN Center for Integrative Medical Sciences), Takayuki Abe(Keio University), Shigehisa Kitano(Tokyo National Hospital)
Cited by 160
Related Papers
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
|New England Journal of Medicine|2012|2.1k
Inflammation-free, gas-permeable, lightweight, stretchable on-skin electronics with nanomeshes
|Nature Nanotechnology|2017|1.1k
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments
|Cancer Cell|2022|828
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
|Nature Immunology|2020|810
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus
|Journal of the American Academy of Dermatology|2008|586